The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors

Clinical Immunology

Volumn 152, Issue 1-2, 2014, Pages 48-57

  Nellore, Anoma ^a   Liu, Bianling ^a   Patsoukis, Nikolaos ^a   Boussiotis, Vassiliki A ^a   Li, Lequn ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cdk2; Graft versus host disease; T cells; T regulatory cells

Indexed keywords

CD71 ANTIGEN; CYCLIN DEPENDENT KINASE 2; GAMMA INTERFERON; HISTONE H1; HISTONE H3; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; LEUKEMIA ANTIGEN; ROSCOVITINE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; WILM TUMOR 1 PROTEIN;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; ENZYME INACTIVATION; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENE CONTROL; GENE EXPRESSION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; WESTERN BLOTTING;

CDK2; GRAFT VERSUS HOST DISEASE; T CELLS; T REGULATORY CELLS;

CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYCLIN-DEPENDENT KINASE 2; DENDRITIC CELLS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN KINASE INHIBITORS; PURINES; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS; WT1 PROTEINS;

EID: 84896957389     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.02.015     Document Type: Article

References (42)

1. Ferrara J.L., Reddy P. Pathophysiology of graft-versus-host disease. Semin. Hematol. 2006, 43:3-10.
2. Appelbaum F.R. Haematopoietic cell transplantation as immunotherapy. Nature 2001, 411:385-389.
3. Champlin R., Khouri I., Kornblau S., Marini F., Anderlini P., Ueno N.T., Molldrem J., Giralt S. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol. Oncol. Clin. North Am. 1999, 13:1041-1057. (vii-viii).
4. Reisner Y., Kapoor N., Kirkpatrick D., Pollack M.S., Dupont B., Good R.A., O'Reilly R.J. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981, 2:327-331.
5. Prentice H.G., Blacklock H.A., Janossy G., Bradstock K.F., Skeggs D., Goldstein G., Hoffbrand A.V. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet 1982, 1:700-703.
6. Filipovich A.H., McGlave P.B., Ramsay N.K., Goldstein G., Warkentin P.I., Kesey J.H. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet 1982, 1:1266-1269.
7. Rodt H., Kolb H.J., Netzel B., Haas R.J., Wilms K., Gotze C.B., Link H., Thierfelder S. Effect of anti-T-cell globulin on GVHD in leukemic patients treated with BMT. Transplant. Proc. 1981, 13:257-261.
8. Waldmann H., Polliak A., Hale G., Or R., Cividalli G., Weiss L., Weshler Z., Samuel S., Manor D., Brautbar C., et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984, 2:483-486.
9. Goldman J.M., Gale R.P., Horowitz M.M., Biggs J.C., Champlin R.E., Gluckman E., Hoffmann R.G., Jacobsen S.J., Marmont A.M., McGlave P.B., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann. Intern. Med. 1988, 108:806-814.
10. Couriel D., Canosa J., Engler H., Collins A., Dunbar C., Barrett A.J. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant. 1996, 18:347-353.
11. Abbas A.K., Lohr J., Knoechel B. Balancing autoaggressive and protective T cell responses. J. Autoimmun. 2007, 28:59-61.
12. Appleman L.J., Boussiotis V.A. T cell anergy and costimulation. Immunol. Rev. 2003, 192:161-180.
13. Wells A.D. Cyclin-dependent kinases: molecular switches controlling anergy and potential therapeutic targets for tolerance. Semin. Immunol. 2007, 19:173-179.
14. Rowell E.A., Wang L., Hancock W.W., Wells A.D. The cyclin-dependent kinase inhibitor p27kip1 is required for transplantation tolerance induced by costimulatory blockade. J. Immunol. 2006, 177:5169-5176.
15. Li L., Iwamoto Y., Berezovskaya A., Boussiotis V.A. A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat. Immunol. 2006, 7:1157-1165.
16. Berthet C., Rodriguez-Galan M.C., Hodge D.L., Gooya J., Pascal V., Young H.A., Keller J., Bosselut R., Kaldis P. Hematopoiesis and thymic apoptosis are not affected by the loss of Cdk2. Mol. Cell. Biol. 2007, 27:5079-5089.
17. Li L., Wang H., Kim J.s., Pihan G., Boussiotis V.A. The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD. Cell Cycle 2009, 8:1794-1802.
18. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., Moulinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 1997, 243:527-536.
19. Ge X., Brown J., Sykes M., Boussiotis V.A. CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors. Biol. Blood Marrow Transplant. 2008, 14:518-530.
20. Patsoukis N., Brown J., Petkova V., Liu F., Li L., Boussiotis V.A. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci. Signal. 2012, 5:ra46.
21. Bach F.H. Differential cellular immune responsiveness to systems of the major histocompatibility complex. J. Allergy Clin. Immunol. 1976, 57:95-111.
22. Amrolia P.J., Muccioli-Casadei G., Yvon E., Huls H., Sili U., Wieder E.D., Bollard C., Michalek J., Ghetie V., Heslop H.E., Molldrem J.J., Rooney C.M., Schlinder J., Vitetta E., Brenner M.K. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 2003, 102:2292-2299.
23. Solomon S.R., Tran T., Carter C.S., Donnelly S., Hensel N., Schindler J., Bahceci E., Ghetie V., Michalek J., Mavroudis D., Read E.J., Vitetta E.S., Barrett A.J. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy 2002, 4:395-406.
24. Ferrara J.L., Deeg H.J. Graft-versus-host disease. N. Engl. J. Med. 1991, 324:667-674.
25. Rezvani K., Brenchley J.M., Price D.A., Kilical Y., Gostick E., Sewell A.K., Li J., Mielke S., Douek D.C., Barrett A.J. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin. Cancer Res. 2005, 11:8799-8807.
26. Edinger M., Hoffmann P., Ermann J., Drago K., Fathman C.G., Strober S., Negrin R.S. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 2003, 9:1144-1150.
27. Tran D.Q., Ramsey H., Shevach E.M. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007, 110:2983-2990.
28. Wang J., Ioan-Facsinay A., van der Voort E.I., Huizinga T.W., Toes R.E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur. J. Immunol. 2007, 37:129-138.
29. Chen S., Bohrer L.R., Rai A.N., Pan Y., Gan L., Zhou X., Bagchi A., Simon J.A., Huang H. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat. Cell Biol. 2010, 12:1108-1114.
30. Molinsky J., Klanova M., Maswabi B., Soukup T., Trneny M., Necas E., Zivny J., Klener P. In vivo growth of mantle cell lymphoma xenografts in immunodeficient mice is positively regulated by VEGF and associated with significant up-regulation of CD31/PECAM1. Folia Biol. (Praha) 2013, 59:26-31.
31. Vandenbosch R., Borgs L., Beukelaers P., Foidart A., Nguyen L., Moonen G., Berthet C., Kaldis P., Gallo V., Belachew S., Malgrange B. CDK2 is dispensable for adult hippocampal neurogenesis. Cell Cycle 2007, 6:3065-3069.
32. Li L., Godfrey W.R., Porter S.B., Ge Y., June C.H., Blazar B.R., Boussiotis V.A. CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood 2005, 106:3068-3073.
33. Sherr C.J., Roberts J.M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004, 18:2699-2711.
34. Zoja C., Casiraghi F., Conti S., Corna D., Rottoli D., Cavinato R.A., Remuzzi G., Benigni A. Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. Arthritis Rheum. 2007, 56:1629-1637.
35. Pezzotta A., Mister M., Monteferrante G., Cassis L., Azzollini N., Aiello S., Satta M., Benigni A., Remuzzi G., Noris M. Effect of seliciclib (CYC202, R-roscovitine) on lymphocyte alloreactivity and acute kidney allograft rejection in rat. Transplantation 2008, 85:1476-1482.
36. Chunder N., Wang L., Chen C., Hancock W.W., Wells A.D. Cyclin-dependent kinase 2 controls peripheral immune tolerance. J. Immunol. 2012, 189:5659-5666.
37. Harbour J.W., Luo R.X., Dei Santi A., Postigo A.A., Dean D.C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999, 98:859-869.
38. Harbour J.W., Dean D.C. Chromatin remodeling and Rb activity. Curr. Opin. Cell Biol. 2000, 12:685-689.
39. Harbour J.W., Dean D.C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 2000, 14:2393-2409.
40. Matsuura I., Denissova N.G., Wang G., He D., Long J., Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004, 430:226-231.
41. Gorelik L., Flavell R.A. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2002, 2:46-53.
42. He L., Fan C., Gillis A., Feng X., Sanatani M., Hotte S., Kapoor A., Tang D. Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma. Biochim. Biophys. Acta 2007, 1772:1134-1142.